Journal: Diabetes Therapy
Article Title: Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease
doi: 10.1007/s13300-025-01750-7
Figure Lengend Snippet: Outcomes: Optum ® EHR. a Incidence rates of primary outcomes, SGLT2i cohort. b Cumulative incidence of secondary outcomes, SGLT2i cohort. c Incidence rates of primary outcomes, GLP-1 RA cohort. d Cumulative incidence of secondary outcomes, GLP-1 RA cohort. CI confidence internal, eGFR estimated glomerular filtration rate, GLP-1 RA glucagon-like peptide-1 receptor agonists, IR incidence rate, Optum® EHR Optum ® de-identified Electronic Health Record data set, SGLT2i sodium-glucose cotransporter 2 inhibitors
Article Snippet: This was a multidatabase, multinational cohort study aiming to describe the incidence of cardiorenal events in separate, non-mutually exclusive cohorts of patients with both CKD and T2D initiating therapy with either an SGLT2i or GLP-1 RA using secondary data from four participating data sources: two population-based data sources in Europe (Danish National Health Registers [DNHR] and Valencia Health System Integrated Database [VID] in Spain); one hospital-based CKD registry in Japan (Japan Chronic Kidney Disease Database Extension [J-CKD-DB-Ex]); and one electronic health record (EHR) database in the US (Optum ® de-identified Electronic Health Record data set [Optum ® EHR]).
Techniques: Filtration